Clinical Trials on Recurrent Ovarian Carcinoma in Norway

Total 469 results

Steinar Aamdal

Terminated

Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Recurrent Epithelial Ovarian Cancer

Norway
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Nordic Society of Gynaecological Oncology - Clinical...

Completed

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Ovarian Epithelial Cancer Recurrent

Denmark, Finland, Norway
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Haukeland University Hospital
Helse Stavanger HF; Sorlandet Hospital HF

Recruiting

The INFLUENCE of Cytoreduction on PRO in EOC (INFLUENCE)

Epithelial Ovarian Cancer

Norway
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
Haukeland University Hospital

Completed

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (IMPACT)

Ovarian Cancer

Norway
Oslo University Hospital
Institute for Molecular Medicine

Recruiting

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma (ISM-GBM)

Recurrent Glioblastoma

Norway
Haukeland University Hospital
Northwell Health; University of Bergen; Weill Medical College of Cornell University and other collaborators

Completed

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma (SAS-GKRS)

Glioma | Glioblastoma | Recurrent Glioblastoma

Norway
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Nordic Society of Gynaecological Oncology - Clinical...

Withdrawn

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Ovarian Cancer

Norway, Denmark, Finland
Oslo University Hospital

Recruiting

Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers

Locally Advanced Pelvic Cancer That Require Pelvic Exenteration

Norway
Kancera AB
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Recruiting

A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (KANDOVA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Denmark, Norway, Sweden
Oncoinvent AS

Active, not recruiting

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

Ovarian Cancer | Peritoneal Carcinomatosis

Belgium, Spain, Norway
Nordic Society of Gynaecological Oncology - Clinical...
European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic...

Completed

Trial in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

Norway, Finland, Denmark
Sorlandet Hospital HF
University of Surrey

Completed

Single Versus Conventional Laparoscopy for Benign Adnexal Disease

Ovarian Cyst

Norway
University of Oslo
Göteborg University; UMC Utrecht; Medical University of Lodz; Amsterdam UMC, location...

Enrolling by invitation

The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI (ImpresUWP3)

Recurrent Urinary Tract Infection

Netherlands, Norway, Poland, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
AGO Study Group
GERCOR - Multidisciplinary Oncology Cooperative Group; Nordic Society of Gynaecological...

Completed

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (AGO-OVAR9)

Ovarian Cancer | Fallopian Tube Cancer

Norway, Germany, France, Denmark
Kristina Lindemann
University Hospital of North Norway; Haukeland University Hospital; Sorlandet... and other collaborators

Completed

Real-life Use of Niraparib in a Patient Access Program in Norway

Ovarian Cancer | Peritoneal Cancer

Norway
Haukeland University Hospital

Unknown

Causes and Consequences of Primary Ovarian Insufficiency (Clinical POI)

Primary Ovarian Insufficiency | Premature Menopause

Norway
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
Catharina Ziekenhuis Eindhoven

Recruiting

Induction Chemotherapy for Locally Recurrent Rectal Cancer (PelvEx II)

Recurrent Rectal Cancer

Netherlands, Sweden, Belgium, Norway, Portugal
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin (FlowMet)

Polycystic Ovary Syndrome

Norway
Norwegian University of Science and Technology

Terminated

Metformin in Assisted Reproduction-MET-AR-study

Polycystic Ovary Syndrome

Norway
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study (pilPregMet)

Polycystic Ovary Syndrome

Norway
Oslo University Hospital
The Research Council of Norway

Recruiting

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies (PSM)

Mesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian Carcinoma

Norway
Medical University of Vienna

Recruiting

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT (MEMMAT)

Medulloblastoma Recurrent | Ependymoma Recurrent | ATRT Recurrent

Austria, Sweden, France, Spain, United States, Czechia, Denmark, Norway
Norwegian University of Science and Technology

Completed

High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

Norway
University of Bergen
Sorlandet Hospital HF

Unknown

Vestibular System in Migrainous Vertigo Patients

Migraine Disorders | Migraine Variant | Episodic Recurrent Vertigo

Norway
M.D. Anderson Cancer Center
United States Department of Defense

Active, not recruiting

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

Ovarian Cancer

United States
Nordic Society of Gynaecological Oncology - Clinical...
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical...

Completed

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Italy, Canada, Israel, Norway, Belgium, Netherlands, Denmark, Portugal, Spain, United States
Norwegian University of Science and Technology
St. Olavs Hospital; Liverpool John Moores University; Australian Catholic University

Completed

Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome (HIT-FAT)

Polycystic Ovary Syndrome

Australia, Norway
Norwegian University of Science and Technology
St. Olavs Hospital; Liverpool John Moores University; Australian Catholic University

Completed

Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training (IMPROV-IT)

Polycystic Ovary Syndrome

Australia, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Ferring Pharmaceuticals

Completed

Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice (NORSOS)

Controlled Ovarian Stimulation

Denmark, Norway, Sweden, Switzerland
The Hospital of Vestfold
Oslo University Hospital

Completed

The Female Health Dietary Intervention Study (FEMIN)

Polycystic Ovary Syndrome | Morbid Obesity

Norway
Hoffmann-La Roche

Completed

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Ovarian Cancer

France, Spain, Brazil, United Kingdom, Netherlands, Italy, Russian Federation, Sweden, Norway
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
AstraZeneca
Parexel; Covance; Iqvia Pty Ltd; Theradex; Myriad Genetics, Inc.

Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)

Non-Germline BRCA Mutated Ovarian Cancer

Italy, Spain, Sweden, Canada, Czechia, Poland, United Kingdom, Israel, Austria, Belgium, Switzerland, Netherlands, Bulgaria, Finland, Norway, Denmark, Slovenia, Portugal
Oslo University Hospital

Recruiting

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (MITRIC)

Clear Cell Renal Cell Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Melanoma Stage IV | Cutaneous Squamous Cell Carcinoma | MSI-High

Norway
Oslo University Hospital
Bristol-Myers Squibb

Recruiting

REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)

Head and Neck Squamous Cell Carcinoma

Norway
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer

United States, Spain
Haukeland University Hospital
Ullevaal University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark and other collaborators

Completed

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Neuroendocrine Carcinoma

Norway
Trio Medicines Ltd.
Norwegian University of Science and Technology

Terminated

YF476 and Type I Gastric Carcinoids (Norway)

Chronic Atrophic Gastritis | Hypergastrinemia | Type I Gastric Carcinoids

Norway

Clinical Trials on Recurrent Ovarian Carcinoma in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations